| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Dendreon's New 'hold' Rating At A.g.edwards
Posted on 05/03/2007 08:33:48 | Link | Post Comment
Jon C. Ogg
24/7 Wall St.
A.G.Edwards (AGE) has initiated the recently volatile and controversial Dendreon (DNDN) with a Hold/Speculative rating. The summary points are that it is starting the biotech as a Hold rated stock for Speculative investors.
It sees significant risks surrounding the May 15th PDUFA action date for Provenge for prostate cancer. This notes that Provenge was the subject of a recent panel meeting where committee members voted unanimously on the Safety and 13-4 on the Efficacy of Provenge.
A.G.Edwards notes that beyond a positive panel vote, there may be political forces within the Center for Biologics Evaluation and Research that increases the odds of Provenge being approved. It notes that, however, given that Provenge failed to achieve primary or secondary endpoints in either Phase II trial and that the primary statistical analysis for comparing overall survival was not pre-specified. A.G.Edwards believes that additional confirmatory data may be required by the agency. After surveying 16 oncologists and 14 urologists, the brokerage firm found that oncologists were mixed 50%/50% on whether Provenge should be approved and that urologists favored approval 71.4% to 28.6%.
The A.G.Edwards' summary ends with "Nevertheless we recommend that investors stay on the sidelines."
Furthermore it notes that Dendreon is not profitable and is not expected to be profitable until 2011. A.G.Edwards notes that an "Approvable Letter" and request for more data could be an outcome of the PDUFA, but also notes the flipside that the agency would be viewed as not looking out for the interest of patients' best interest if they hold this up. That's a coin toss there.
It is worth noting that Needham reiterated their Buy rating with a $22.00 target, and that was what energized the shares today. Shares of Dendreon (DNDN-NASDAQ) closed up 6.3% at $17.20 in regular trading. Remember that two analysts can look at the exact same data and take away opposite opinions, and that appears no different here.
As far as looking at options for any direction, a MAY08 $17.50 Straddle (own Put and Call) to play volatility would cost you $10.30 based upon last look at the end of the day. Here is what we noted just last week on this one, and it has links to several prior issues as well.
Source: 247WallSt.com
RELATED READING:
- Dendreon: Countdown to FDA
- Cramer Looking For the Next Dendreon
- Out of Dendreon; Another Chance in May
_____________________
24/7 Wall St.
A.G.Edwards (AGE) has initiated the recently volatile and controversial Dendreon (DNDN) with a Hold/Speculative rating. The summary points are that it is starting the biotech as a Hold rated stock for Speculative investors.
It sees significant risks surrounding the May 15th PDUFA action date for Provenge for prostate cancer. This notes that Provenge was the subject of a recent panel meeting where committee members voted unanimously on the Safety and 13-4 on the Efficacy of Provenge.
A.G.Edwards notes that beyond a positive panel vote, there may be political forces within the Center for Biologics Evaluation and Research that increases the odds of Provenge being approved. It notes that, however, given that Provenge failed to achieve primary or secondary endpoints in either Phase II trial and that the primary statistical analysis for comparing overall survival was not pre-specified. A.G.Edwards believes that additional confirmatory data may be required by the agency. After surveying 16 oncologists and 14 urologists, the brokerage firm found that oncologists were mixed 50%/50% on whether Provenge should be approved and that urologists favored approval 71.4% to 28.6%.
The A.G.Edwards' summary ends with "Nevertheless we recommend that investors stay on the sidelines."
Furthermore it notes that Dendreon is not profitable and is not expected to be profitable until 2011. A.G.Edwards notes that an "Approvable Letter" and request for more data could be an outcome of the PDUFA, but also notes the flipside that the agency would be viewed as not looking out for the interest of patients' best interest if they hold this up. That's a coin toss there.
It is worth noting that Needham reiterated their Buy rating with a $22.00 target, and that was what energized the shares today. Shares of Dendreon (DNDN-NASDAQ) closed up 6.3% at $17.20 in regular trading. Remember that two analysts can look at the exact same data and take away opposite opinions, and that appears no different here.
As far as looking at options for any direction, a MAY08 $17.50 Straddle (own Put and Call) to play volatility would cost you $10.30 based upon last look at the end of the day. Here is what we noted just last week on this one, and it has links to several prior issues as well.
Source: 247WallSt.com
RELATED READING:
- Dendreon: Countdown to FDA
- Cramer Looking For the Next Dendreon
- Out of Dendreon; Another Chance in May
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Editorial Spotlight - Tue Aug 19, 2008 05:27PM
College, they say, provides the best return of any inves [read more]
College, they say, provides the best return of any inves [read more]
Morpheus Trading - Tue Aug 19, 2008 02:19AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Wed Aug 20, 2008 02:40AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home